Sheen Wang
YOU?
Author Swipe
View article: Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915 Open
Purpose CheckMate 915 ( NCT03068455 ) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that corr…
View article: Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022
Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022 Open
Despite high response rates, anti–programmed death 1 (anti–PD-1) monotherapy eventually fails in most patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) and is ineffective in most other B-cell malignancies. The lymphocyte activa…